Open AccessA new allergic rhinitis therapy (MP29‐02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
Author(s) -
Hellings Peter,
Bachert Claus,
Mösges Ralph,
Scadding Glenis,
Munzel Ullrich,
Fokkens Wytske
Publication year - 2015
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-5-s4-p34
Subject(s) - medicine , nasal congestion , fluticasone propionate , rhinorrhea , post hoc analysis , placebo , azelastine , anesthesia , surgery , nose , corticosteroid , alternative medicine , pathology
Methods Six hundred and ten moderate-to-severe SAR patients (≥12 yrs) were randomized into a double-blind, PLAcontrolled, 14-day, parallel-group, trial (NCT00660517) to MP29-02*, AZE, FP or PLA nasal sprays (1 spray/ nostril bd; daily dose: AZE=548μg; FP=200μg) [1]. Change from baseline (CFB) in reflective total of 7 symptom scores (rT7SS; AM + PM, max=42) was assessed post-hoc. CFB in rT7SS and each nasal (congestion, itching, rhinorrhea, sneezing) and ocular symptom (itching, redness, watering; max=6 each) was assessed over time.